GeneSystem Co

GeneSystem Co FCF/Debt

The Free Cash Flow to Debt Ratio of GeneSystem Co (363250.KQ) as of Nov 1, 2026 is -371.20 %. In the previous year, Free Cash Flow to Debt Ratio was -246.80 % — a change of 50.41% (lower).

FCF/Debt

-371.20 %

YoY

50.41%

Last updated:

Free Cash Flow to Debt Ratio of GeneSystem Co is 2025 -371.20 % . Free Cash Flow to Debt Ratio of GeneSystem Co was 2024 -246.80 % . It decreases by 50.41% lower compared to the previous year.

The GeneSystem Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-52.10 KRW
Jan 1, 2019
-101.96 KRW
Jan 1, 2020
-54.00 KRW
Jan 1, 2021
16.67 KRW
Jan 1, 2022
-169.05 KRW
Jan 1, 2023
-207.98 KRW
Jan 1, 2024
-246.80 KRW
Jan 1, 2025
-371.20 KRW
The GeneSystem Co FCF/Debt history
YEARFCF/DebtYoY
-371.20 %+50.41%
-246.80 %+18.66%
-207.98 %+23.03%
-169.05 %-1,113.96%
16.67 %-130.87%
-54.00 %-47.04%
-101.96 %+95.72%
-52.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Free Cash Flow to Debt Ratio of GeneSystem Co is -371.20 % in 2025.

Free Cash Flow to Debt Ratio of GeneSystem Co changed from -246.80 % to -371.20 %, representing a 50.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GeneSystem Co

All Key Metrics — GeneSystem Co